$3.7MPre-Seed, 18 February 2026
Pre-seed funds in vivo efficacy studies, its AI peptide discovery engine and lead candidate selection in oncology.
- Amount
- $3.7M
- Stage
- Pre-Seed
- Announced
- 18 February 2026
- Lead
- Lifespan Vision Ventures
- Other investors
- Freeflow Ventures, Valuence Ventures, Eisai Innovation, SBI US Gateway Fund
- Use of funds
- Pre-seed funds in vivo efficacy studies, its AI peptide discovery engine and lead candidate selection in oncology.
- Checked
- Announced by the company
- Sources
- Sift Biosciences announces oversubscribed $3.7M pre-seed businesswire.com
Sift Biosciences announces oversubscribed $3.7M pre-seed businesswire.com